UK markets open in 3 hours 26 minutes

Chr. Hansen Holding A/S (CHR.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
429.40+10.10 (+2.41%)
At close: 04:59PM CEST
Full screen
Previous close419.30
Bid427.90 x 0
Ask429.40 x 0
Day's range419.90 - 432.00
52-week range360.10 - 604.00
Avg. volume116,975
Market cap56.51B
Beta (5Y monthly)0.27
PE ratio (TTM)34.13
EPS (TTM)12.58
Earnings date12 Oct 2023
Forward dividend & yield7.04 (1.68%)
Ex-dividend date24 Nov 2022
1y target est514.47
  • Globe Newswire

    Major shareholder announcements from Burlington Loan Management DAC and Davidson Kempner Capital Management LP

    September 27, 2023 – Company announcement no. 8 Please see attachment. Contact information Investor RelationsAnders Mohr Christensen+45 2515 Press RelationsSanne Seyer-Hansen+45 6038 About Chr. Hansen Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen, we are strongly positioned to drive positive change through

  • Globe Newswire

    Update on the combination of Novozymes and Chr. Hansen: Chinese merger approval granted, supporting the path to completion

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL. SEPTEMBER 4, 2023 On December 12, 2022, Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") announced that Novozymes and Chr. Hansen propose to combine and create a leading global biosolutions partner by way of a statutory merger of the two companies. Re

  • Globe Newswire

    Chr. Hansen Holding A/S Interim Report Q3 2022/23

    July 6, 2023 – Company announcement no. 7 Strong execution by the organization drives solid Q3 results Statement by CEO Mauricio Graber: “The solid results for Q3 prove the strength of the Chr. Hansen organization which continues to deliver first-class products and innovative solutions to customers around the world, while the process with Novozymes to complete the proposed merger is progressing. Organic growth came in at 9%, driven mainly by pricing initiatives. EBIT b.s.i. increased by 9% despi